NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced that its management team will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, at 3:30 PM ET in a fireside chat format.
The webcast will be available on the company’s website News & Events page for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – NBP
In the May 12 session, NBP declined 1.90%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Leadership appointment | Positive | -0.4% | Named new President and CCO to drive commercial strategy and pipeline value. |
| Apr 07 | Earnings and update | Neutral | -1.2% | Reported 2025 results, detailed cash of $210.8M, losses, and pipeline progress. |
| Mar 16 | Regulatory pathway | Positive | +1.4% | Announced FDA alignment on potential accelerated approval path for givastomig. |
| Mar 09 | Clinical data update | Positive | +0.1% | Released positive VIS-101 Phase 2a wet AMD data with strong efficacy and safety. |
| Mar 03 | Event announcement | Neutral | -7.3% | Announced upcoming business update call to review VIS-101 Phase 2a data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive pipeline and leadership news often saw flat to negative next-day moves, indicating a tendency toward muted or contrarian reactions around announcements.
Over the last few months, NovaBridge has focused on advancing its oncology and ophthalmology pipeline while reshaping leadership. Positive updates on givastomig and VIS-101 in March 2026, including FDA alignment on an accelerated approval pathway and encouraging Phase 2a wet AMD data, led to only modest share moves. An April 20-F detailed larger losses but a cash position of $210.8M and runway into 2028, while a new President and CCO was appointed on Apr 22, 2026. Against this backdrop, today’s investor conference appearance fits the ongoing visibility and investor-relations push.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of NovaBridge’s management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference being held on May 19, 2026.
Conference details are as follows:
H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat
Date: Tuesday, May 19, 2026
Time: 3:30 PM ET
Webcast Link: Here
The webcast of the company presentation will be accessible on the News & Events page of the NovaBridge website for 90 days.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential first-in-class and best-in-class, Claudin 18.2 X 4-1BB bispecific antibody, and VIS-101, purpose-designed, potential best-in-class, dual VEGF-A X ANG-2 inhibitor.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more rapid, robust and durable treatment responses for patients with retinal vascular diseases including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed a randomized, dose-ranging Phase 2a study for wet AMD and expects to initiate a dose-determining Phase 2b study in H2 2026. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
